Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.

Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

In terms of value market share, Novo Nordisk dominates 44.50% of the global insulin market share ... A similar argument can be made when considering the much more famous PE Ratio, in this case ...

Nonprescription insulin is made from older formulations of diabetes ... Walmart teamed up with drugmaker Novo Nordisk to sell its own brand, called ReliOn insulin, which sells for as little ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...

Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...

January is a big time for drugmakers to hike prices. This year saw higher prices for 575 medications so far, including ...